View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Sygenus Shows Longer Lasting Effect on Pain than Morphine

🕔9/26/2017 9:29:00 AM 1360

Regeneus Ltd (ASX:RGS) , a clinical-stage regenerative medicine company, today announced that a preclinical post-operative pain study has shown that topical application of Sygenus, has significantly greater and longer lasting analgesic effect than an injection of morphine.

Read Full Article

Regeneus Ltd (ASX:RGS) Edison Investment Report Issued

🕔9/11/2017 7:52:04 AM 1266

The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.6m

🕔8/29/2017 11:29:46 AM 1095

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.

Read Full Article

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) Interview with John Martin on Progenza and the Platform Technology

🕔8/25/2017 10:15:41 AM 3485

Regeneus Ltd (ASX:RGS) CEO John Martin talks on the release of the financial results following the company's significant progress with Japanese partner Asahi Glass Ltd (AGC) (TYO:5201)

Read Full Article

Regeneus Ltd (ASX:RGS) FY17 Results Announcement

🕔8/22/2017 9:57:16 AM 1446

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Full-Year Report for the 12 months ending 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/26/2017 9:30:49 AM 1494

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent Allowed for Sygenus Secretions Technology for Acne

🕔7/10/2017 9:26:34 AM 1589

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat acne. We recently informed the market of the new name for the secretions platform in our Q2 2017 Update.

Read Full Article

Regeneus Ltd (ASX:RGS) Q2 2017 Update

🕔7/5/2017 10:34:22 AM 1483

Regeneus Ltd (ASX:RGS) provides the Company's latest newsletter for the quarter ended 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) to Receive Milestone Payment for Successful Phase I

🕔6/21/2017 9:10:44 AM 1382

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it will receive a milestone payment of US$1m from AGC for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis. The company reported on the positive results of the trial on 22 May 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation to ChinaBio Partnering Forum

🕔5/31/2017 8:26:23 AM 1499

Regeneus Ltd (ASX:RGS) is pleased to provide the Company's latest presentation to ChinaBio Partnering Forum.

Read Full Article
###

52,386 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 239) (Last 30 Days: 2388) (Since Published: 28689) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media